GlaxoSmithKline's Revolade approved for new indication in Europe

GlaxoSmithKline (GSK) gets a HCV-associated thrombocytopenia indication for Revolade from the European Commission.

Thrombocytopenia can limit or inhibit patients' pIFN-based treatment. (PR)

Revolade was discovered through a collaboration with Ligand Pharmaceuticals (LGND).

From other sites
Comments (1)
  • bberuch
    , contributor
    Comments (314) | Send Message
    note that LGND (a much smaller company) will see bigger % impact of approval due to it's relative size.
    I hold a position in LGND.
    24 Sep 2013, 09:58 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs